El-MesallamyHOHamdyNMSalmanTMMahmoudS. Adiponectin and E-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease(s). Angiology. 2011;in press.
2.
KatsikiNMikhailidisDPGotzamani-PsarrakouAYovosJGKaramitsosD. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets. 2011;15(4):401–420.
3.
KashyapSRRomanLJMandarinoLDeFronzoRBajajM. Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. Metab Syndr Relat Disord. 2010;8(5):459–463.
4.
TaniguchiAFukushimaMOhyaM. Interleukin 6, adiponectin, leptin, and insulin resistance in nonobese Japanese type 2 diabetic patients. Metabolism. 2006;55(2):258–262.
5.
KowalskaIStraczkowskiMNikoajukA. Plasma adiponectin and E-selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism. Adv Med Sci. 2006;51:94–97.
6.
Brochu-GaudreauKRehfeldtCBlouinRBordignonVMurphyBDPalinMF. Adiponectin action from head to toe. Endocrine. 2010;37(1):11–32.
7.
GoldsteinBJScaliaRGMaXL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med. 2009;6(1):27–35.
8.
CuiJPanseSFalknerB. The role of adiponectin in metabolic and vascular disease: a review. Clin Nephrol. 2011;75(1):26–33.
9.
KawanoJAroraR. The role of adiponectin in obesity, diabetes, and cardiovascular disease. J Cardiometab Syndr. 2009;4(1):44–49.
10.
ShibataROuchiNMuroharaT. Adiponectin and cardiovascular disease. Circ J. 2009;73(4):608–614.
11.
KirisITekinIYesildagA. Inverse relationship between adiponectin levels and subclinical carotid atherosclerosis in patients undergoing coronary artery bypass grafting. Int Heart J. 2006;47(6):855–866.
12.
WolkRBergerPLennonRJBrilakisESDavisonDESomersVK. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2007;28(3):292–298.
13.
DekkerJMFunahashiTNijpelsG. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab. 2008;93(4):1489–1496.
14.
YilmazMISaglamMQureshiAR. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008;23(5):1621–1627.
15.
KatoKOsawaHOchiM. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy. Clin Endocrinol (Oxf). 2008;68(3):442–449.
16.
ZietzBBuechlerCKobuchKNeumeierMSchölmerichJSchäfflerA. Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2008;116(9):532–536.
17.
TuttolomondoALa PlacaSDi RaimondoD. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity. Cardiovasc Diabetol. 2010;9:50.
18.
HajerGRvan der GraafYOlijhoekJKEdlingerMVisserenFL. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease. Am Heart J. 2007;154(4):750.e1–e7.
19.
NomuraSShouzuAOmotoSNishikawaMFukuharaS. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol. 2000;121(3):437–443.
20.
HaubnerFLehleKMünzelDSchmidCBirnbaumDEPreunerJG. Hyperglycemia increases the levels of vascular cellular adhesion molecule-1 and monocyte-chemoattractant-protein-1 in the diabetic endothelial cell. Biochem Biophys Res Commun. 2007;360(3):560–565.
21.
FengLMatsumotoCSchwartzASchmidtAMSternDMPile-SpellmanJ. Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care. 2005;28(2):379–384.
22.
DavìGTuttolomondoASantilliF. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb. 2009;16(6):707–713.
23.
PiemontiLCaloriGLattuadaG. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care. 2009;32(11):2105–2110.
24.
YuasaSMaruyamaTYamamotoY. MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract. 2009;86(3):193–198.
25.
OhIKKimSWOhJLeeTSHuhK. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res. 2010;35(12):1116–1127.
26.
GiuntiSBaruttaFPerinPCGrudenG. Targeting the MCP-1/CCR2 System in diabetic kidney disease. Curr Vasc Pharmacol. 2010;8(6):849–860.
27.
ReillyMPIqbalNSchuttaM. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(8):3872–3878.
28.
KimSKKimHJAhnCW. Hyperleptinemia as a robust risk factor of coronary artery disease and metabolic syndrome in type 2 diabetic patients. Endocr J. 2008;55(6):1085–1092.
29.
TaniguchiAFukushimaMNakaiY. Factors responsible for the evolution of insulin resistance in Japanese type 2 diabetic patients: association with atherosclerosis. Diabetes Res Clin Pract. 2007;77(suppl 1):S213–S219.
30.
NishioKSakuraiMKusuyamaT. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006;29(1):101–106.
31.
RuigeJBMertensIConsidineRVPaelinckBPVan GaalLF. Opposite effects of insulin-like molecules and leptin in coronary heart disease of type 2 diabetes Preliminary data. Int J Cardiol. 2006;111(1):19–25.
32.
BountourisIParaskevasKIKoutouzisM. Serum leptin levels in patients undergoing carotid endarterectomy: a pilot study. Angiology. 2009;60(6):698–704.
33.
AbdellaNAMojiminiyiOAMoussaMA. Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance. Diabet Med. 2005;22(3):278–285.
34.
ShettyGKEconomidesPAHortonESMantzorosCSVevesA. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004;27(10):2450–2457.
35.
TakataYOsawaHKurataM. Hyperresistinemia is associated with coexistence of hypertension and type 2 diabetes. Hypertension. 2008;51(2):534–539.
36.
OnYKParkHKHyonMSJeonES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J. 2007;71(6):868–873.
37.
OsawaHOchiMTabaraY. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf). 2008;69(1):74–80.
38.
OsawaHOchiMKatoK. Serum resistin is associated with the severity of microangiopathies in type 2 diabetes. Biochem Biophys Res Commun. 2007;355(2):342–346.
39.
MartensFMRabelinkTJop’t RoodtJde KoningEJVisserenFL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J. 2006;27(13):1605–1609.
40.
AkalinAAlatasOColakO. Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients. Eur J Endocrinol. 2008;158(1):47–52.
41.
PuLJLuLShenWF. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J. 2007;71(7):1067–1073.
42.
HirotaTSuzukiEItoI. Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels of tumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2008;82(1):58–65.
43.
LuLPuLJXuXW. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem. 2007;40(11):810–816.
44.
KaulKHodgkinsonATarrJMKohnerEMChibberR. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes?. Curr Diabetes Rev. 2010;6(5):294–303.
45.
LeeJHLeeWKwonOH. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci. 2008;38(4):361–367.
46.
AdamisAPBermanAJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):65–84.
47.
Navarro-GonzálezJFJarqueAMurosMMoraCGarcíaJ. Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy. Cytokine Growth Factor Rev. 2009;20(2):165–173.
48.
DrelVRLupachykSShevalyeH. New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}. Endocrinology. 2010;151(6):2547–2555.
49.
KrayenbuehlPAWiesliPSchmidM. TNF-alpha-308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp Clin Endocrinol Diabetes. 2007;115(5):322–326.
50.
VendrellJFernandez-RealJMGutierrezC. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis. 2003;167(2):257–264.
51.
SouzaJROliveiraRTBlottaMHCoelhoOR. Serum levels of interleukin-6 (Il-6), interleukin-18 (Il-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol. 2008;90(2):86–90.
52.
JohansenOEBirkelandKIOrvikE. Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects. Scand J Clin Lab Invest. 2007;67(3):306–316.
53.
MavridisGSouliouEDizaE. Inflammatory cytokines in insulin-treated patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2008;18(7):471–476.
54.
JamesSKLindahlBTimmerJR. Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). Am J Cardiol. 2006;97(2):167–172.
55.
ShinoharaTTakahashiNYufuK. Role of interleukin-6 levels in cardiovascular autonomic dysfunction in type 2 diabetic patients. Eur J Nucl Med Mol Imaging. 2008;35(9):1616–1623.
56.
LibraMSignorelliSSBevelacquaY. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol. 2006;59(2):211–215.
57.
XuLJiangCQLamTHBaoBChengKKThomasGN. Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: the Guangzhou Biobank Cohort Study-CVD. Clin Endocrinol (Oxf). 2011;74(4):528–531.
58.
Alizadeh DehnaviRBeishuizenEDvan de ReeMA. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus. Eur J Intern Med. 2008;19(2):115–121.
59.
BrazionisLYauJRowleyK. Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes. Diabetes Res Clin Pract. 2010;87(2):192–199.
60.
MadanRGuptBSalujaSKansraUCTripathiBKGulianiBP. Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India. 2010;58:481–484.
61.
EremCHacihasanoğluACelikS. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract. 2005;14(1):22–30.
62.
SzelagBWroblewskiMCastenforsJ. Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes. Diabetes Care. 1999;22(11):1907–1908.
63.
BoylePJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med. 2007;120(9 suppl 2):S12–S17.
64.
DunnEJGrantPJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med. 2005;5(3):323–332.
65.
AthyrosVGTziomalosKKaragiannisAAnagnostisPMikhailidisDP. Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets. 2010;11(1):122–135.
66.
RizosCVLiberopoulosENMikhailidisDPElisafMS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother. 2008;9(7):1087–1108.
67.
ParaskevasKILiapisCDMikhailidisDP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets. 2006;7(6):761–771.
68.
FilippatosTDKiortsisDNLiberopoulosENMikhailidisDPElisafMS. A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005;21(3):457–468.
